Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.45 USD | -8.07% | -3.24% | -38.25% |
May. 09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
May. 09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
Financials (USD)
Sales 2024 * | 370K | Sales 2025 * | 330K | Capitalization | 858M |
---|---|---|---|---|---|
Net income 2024 * | -230M | Net income 2025 * | -266M | EV / Sales 2024 * | 1,069 x |
Net cash position 2024 * | 462M | Net cash position 2025 * | 625M | EV / Sales 2025 * | 707 x |
P/E ratio 2024 * |
-3.63
x | P/E ratio 2025 * |
-3.43
x | Employees | 94 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.26% |
Latest transcript on Viridian Therapeutics, Inc.
1 day | -8.07% | ||
1 week | -3.24% | ||
Current month | +1.43% | ||
1 month | -11.28% | ||
3 months | -27.65% | ||
6 months | -15.30% | ||
Current year | -38.25% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 23-04-30 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 18-01-02 |
Tomas Kiselak
CHM | Chairman | 38 | 20-10-27 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 234 M€ | +5.72% | - | |
0.02% | 2 M€ | -.--% | ||
0.01% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 13.45 | -8.07% | 1,106,910 |
24-05-16 | 14.63 | +2.52% | 807,831 |
24-05-15 | 14.27 | -2.73% | 719,140 |
24-05-14 | 14.67 | +2.30% | 640,880 |
24-05-13 | 14.34 | +3.17% | 630,499 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.25% | 858M | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- VRDN Stock